These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 32227878)

  • 21. Liver as a target for oligonucleotide therapeutics.
    Sehgal A; Vaishnaw A; Fitzgerald K
    J Hepatol; 2013 Dec; 59(6):1354-9. PubMed ID: 23770039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals.
    Campbell MA; Wengel J
    Chem Soc Rev; 2011 Dec; 40(12):5680-9. PubMed ID: 21556437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and biophysical properties of 5'-thio-2',4'-BNA/LNA oligonucleotide.
    Islam MA; Fujisaka A; Mori S; Ito KR; Yamaguchi T; Obika S
    Bioorg Med Chem; 2018 Jul; 26(12):3634-3638. PubMed ID: 29886084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An overview of sugar-modified oligonucleotides for antisense therapeutics.
    Prakash TP
    Chem Biodivers; 2011 Sep; 8(9):1616-41. PubMed ID: 21922654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advances in chemical synthesis of structurally modified bioactive RNAs.
    Li Z; Zhou H; Wu X; Yao H
    Curr Med Chem; 2013; 20(29):3641-54. PubMed ID: 23745561
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances in oligonucleotide synthesis and their applications.
    Vaijayanthi B; Kumar P; Ghosh PK; Gupta KC
    Indian J Biochem Biophys; 2003 Dec; 40(6):377-91. PubMed ID: 22900365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent progress in non-native nucleic acid modifications.
    McKenzie LK; El-Khoury R; Thorpe JD; Damha MJ; Hollenstein M
    Chem Soc Rev; 2021 Apr; 50(8):5126-5164. PubMed ID: 33644787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Therapeutic oligonucleotides: a review].
    Wang X; Xian J; Chen G; Peng H
    Sheng Wu Gong Cheng Xue Bao; 2018 May; 34(5):664-675. PubMed ID: 29893074
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selection of modified oligonucleotides with increased target affinity via MALDI-monitored nuclease survival assays.
    Altman RK; Schwope I; Sarracino DA; Tetzlaff CN; Bleczinski CF; Richert C
    J Comb Chem; 1999; 1(6):493-508. PubMed ID: 10748727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. 2'-Modified oligonucleotides for antisense therapeutics.
    Prakash TP; Bhat B
    Curr Top Med Chem; 2007; 7(7):641-9. PubMed ID: 17430205
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploring site-specific activation of bis-N,N'-dialkylaminophosphordiamidites and the synthesis of morpholinophosphoramidate oligonucleotides.
    Krishna H; Jastrzebska K; Caruthers M
    FEBS Lett; 2019 Jul; 593(13):1459-1467. PubMed ID: 31206627
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Building oligonucleotide therapeutics using non-natural chemistries.
    Wilson C; Keefe AD
    Curr Opin Chem Biol; 2006 Dec; 10(6):607-14. PubMed ID: 17049298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and characterization of 4'-
    Uematsu A; Kajino R; Maeda Y; Ueno Y
    Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):280-291. PubMed ID: 31530080
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aptamers against extracellular targets for in vivo applications.
    Pestourie C; Tavitian B; Duconge F
    Biochimie; 2005; 87(9-10):921-30. PubMed ID: 15963620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Versatile Solid-Phase Approach to the Synthesis of Oligonucleotide Conjugates with Biodegradable Hydrazone Linker.
    Meschaninova MI; Entelis NS; Chernolovskaya EL; Venyaminova AG
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33917095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A highly constrained nucleic acid analog based on α-l-threosamine.
    Morihiro K; Okamoto A
    Nucleosides Nucleotides Nucleic Acids; 2020; 39(1-3):270-279. PubMed ID: 31530088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Backbone modifications in oligonucleotides and peptide nucleic acid systems.
    De Mesmaeker A; Altmann KH; Waldner A; Wendeborn S
    Curr Opin Struct Biol; 1995 Jun; 5(3):343-55. PubMed ID: 7583633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modification of oligonucleotides with weak basic residues via the 2'-O-carbamoylethyl linker for improving nuclease resistance without loss of duplex stability and antisense activity.
    Masaki Y; Yamamoto K; Yoshida K; Maruyama A; Tomori T; Iriyama Y; Nakajima H; Kanaki T; Seio K
    Org Biomol Chem; 2019 May; 17(19):4835-4842. PubMed ID: 31033986
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oligonucleotide analogues: an overview.
    Matteucci M
    Ciba Found Symp; 1997; 209():5-14; discussion 14-8. PubMed ID: 9383565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hybrid lipid oligonucleotide conjugates: synthesis, self-assemblies and biomedical applications.
    Patwa A; Gissot A; Bestel I; Barthélémy P
    Chem Soc Rev; 2011 Dec; 40(12):5844-54. PubMed ID: 21611637
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.